Every material Form 8-K Outset Medical, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Outset Medical reported third quarter 2026 revenue of $33.6 million, up 14% from the prior-year period, and a net loss of $14.7 million, compared with $17.8 million a year earlier. The company reiterated its 2026 revenue guidance of $125 million to $130 million, so shareholders see higher sales and a smaller loss, with no change to the outlook.
Q3 2026 revenue was $33.6 million, up 14% from $29.4 million in Q3 2025; product revenue rose 15% and service and other revenue rose 12%.
Net loss was $14.7 million, or $0.78 per share, versus $17.8 million, or $1.00 per share, in Q3 2025.
Gross margin was 40.7%, up from 39.4% a year earlier; non-GAAP gross margin was 40.8%.
Total cash, cash equivalents, short-term investments and restricted cash was $140.7 million at September 30, 2026, and the company reiterated 2026 revenue guidance of $125 million to $130 million.
Outset Medical said General Counsel John Brottem informed the company on August 27, 2026, that he will leave his role effective September 11, 2026, to pursue other professional opportunities. The filing states the departure is not due to any dispute or disagreement with the company or its management.
John Brottem gave notice on August 27, 2026, and his departure as General Counsel is effective September 11, 2026.
He is leaving to pursue other professional opportunities.
The filing says the departure is not due to any dispute or disagreement with the company or its management.
Outset Medical reported second quarter 2026 revenue of $31.6 million, up 1% from a year earlier, and a net loss of $18.0 million, or $0.97 per share, versus $18.5 million, or $1.04 per share, in the prior-year quarter. The company reiterated its 2026 revenue guidance of $125 million to $130 million, but product revenue and recurring revenue both declined from the prior year.
Revenue of $31.6 million rose 1% from $31.4 million; product revenue fell 5% to $21.9 million and service and other revenue rose 17% to $9.7 million.
Gross margin was 42.0% versus 37.8% a year earlier; net loss was $18.0 million, or $0.97 per share, versus $18.5 million, or $1.04 per share.
2026 revenue guidance of $125 million to $130 million was reiterated, and non-GAAP gross margin is expected in the low-40% to mid-40% range for the full year.
The company signed a three-year, $40 million agreement with HCA Healthcare to refresh its Tablo systems; cash and investments totaled $151.0 million at June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Outset Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →